A biographer and a bioethicist take on the CRISPR revolution
By Jackie Leach Scully,
Nature
| 03. 08. 2021
Thorny ethical questions and bitter scientific competition drive new accounts of the genome-editing story.
CRISPR People: The Science and Ethics of Editing Humans Henry T. Greely, MIT Press (2021)
The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race Walter Isaacson, Simon & Schuster (2021)
What we used to call genetic engineering has been subject to decades of bioethical scrutiny. Then, the arrival of CRISPR — which allows researchers to cut and paste gene sequences with vastly improved accuracy and efficiency — catapulted reassuringly distant science fiction into a pressing reality, and helped to concentrate minds. There’s now enough technical and popular writing on the technology and its ethics to fill many bookshelves.
Given that not even ten years have passed since the first papers showing a practical use for CRISPR in human genome editing, these accounts inevitably go over much of the same territory. The differences are in the authors’ perspectives — broadly enthusiastic about the possibilities of genome editing, or not — and whether the focus is on the discoveries, the ramifications, the personalities involved or some combination. Two new books on the topic differ markedly...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...